

# Assessing experience, safety, and outcomes of the Passio Pump Drainage System

<b>Submission date</b> 19/02/2024	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 28/06/2024	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 11/07/2025	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

The pleural membranes are two thin layers of tissue covering the outside of the lung. Excess fluid can accumulate between these layers (a pleural effusion) causing breathlessness. This fluid can be managed with a semi-permanent catheter called an indwelling pleural catheter (IPC). These IPCs are drained regularly at home to manage the patient's symptoms and prevent effusion recurrence.

If the effusion is drained regularly, the pleura can adhere together, preventing further fluid accumulation (autopleurodesis). Evidence suggests that more frequent drainage promotes more rapid pleurodesis and earlier IPC removal. Unfortunately, due to shortages of community nurses, patients are often drained 3 times weekly, rather than 5 times weekly, as is best practice. Current drainage systems (the BD PleurX drainage system) use vacuum drainage bottles, which require considerable dexterity to use. This prohibits patients from managing their own drainages and increases the burden on community nurses, reducing patients' drainage frequency. It can be challenging to control drainage rates with bottles, which can be uncomfortable.

The Passio Pump Drainage System uses a handheld electronic pump to drain fluid from an IPC into a bag, offering electronic control of drainage. It is more portable and simpler to use, which could allow patients to manage their own drainages more frequently.

ESOP is a randomised-controlled, crossover, exploratory study being run at North Bristol NHS Trust, Bristol, UK. This study aims to gather information regarding the safety, tolerability and patient experience of the Passio Pump Drainage system compared to the BD PleurX drainage system.

### Who can participate?

Patients aged 18 years and over with a recurrent symptomatic malignant pleural effusion requiring an IPC insertion for long-term management within the catchment area of North Bristol NHS Trust.

### What does the study involve?

Participants will be randomly allocated to have inserted either a Passio catheter or a BD PleurX IPC (current standard IPC) with a 3-5 x weekly drainage regimen. They will keep a symptom and drainage diary, with reviews at 2 and 4 weeks to assess whether their effusion has dried up and the catheter can be removed. This study has the potential to inform further research using this

drainage system. Participants will spend the first 2 weeks of the study using the device to which they were randomly allocated, then will switch to the alternative device for the second 2 weeks of the study.

What are the potential benefits and risks of participating?

Everyone who takes part in the study will receive the benefits of having an IPC in place to help manage their symptoms associated with fluid that keeps building back up. If you receive the new drainage system you may be able to have a relative or carer drain your IPC, or drain the IPC yourself (after they/you have received training) rather than a nurse.

If you receive the new drainage system there is more control over the drainage which may reduce the chances of feeling discomfort or pain. The extra chest X-ray at the 2-week visit allows for closer monitoring of any changes to the volume of fluid around your lungs and may result in the IPC being removed early if the fluid is not building back up. Whichever group you are allocated to, your participation in this study will help improve our understanding of patients' experiences of different types of IPC, drainage devices and different drainage schedules. This will benefit patients in your situation in the future.

The study design requires you to have drainages 3-5 x weekly, which could be burdensome for some people. That said, the researchers believe that this drainage regimen will keep your symptoms as manageable as possible and may actually reduce the amount of time that the IPC needs to remain in place, allowing you to return to your normal activities sooner. Several of the chest X-rays required during this study would be needed anyway as part of your routine care. As part of the study, you may need to have 2-3 additional chest X-rays to provide us with a baseline chest X-ray if you haven't had one done recently and to assess whether your effusion has dried up (pleurodesed). Other risks/ disadvantages associated with taking part include attending an extra follow-up appointment 2 weeks after your IPC has been inserted.

Where is the study run from?

North Bristol NHS Trust (UK)

When is the study starting and how long is it expected to run for?

March 2022 to July 2025

Who is funding the study?

It is funded by Bearpac Plc (USA) who make the Bearpac Passio Pump Drainage System

Who is the main contact?

Dr Emma Tucker, Emma.Tucker2@nbt.nhs.uk

## Contact information

### Type(s)

Scientific, Principal investigator

### Contact name

Prof Nick Maskell

### ORCID ID

<https://orcid.org/0000-0002-1276-6500>

### Contact details

Learning and Research Building  
Southmead Hospital  
Southmead Road  
Bristol  
United Kingdom  
BS10 5NB  
+44 (0)1174148033  
Nick.Maskell@bristol.ac.uk

**Type(s)**

Public

**Contact name**

Dr Emma Tucker

**ORCID ID**

<https://orcid.org/0000-0002-3884-1345>

**Contact details**

Academic Respiratory Unit  
North Bristol NHS Trust, Southmead Hospital  
Bristol  
United Kingdom  
BS10 5NB  
+44 (0)1174148114  
Emma.Tucker2@nbt.nhs.uk

**Type(s)**

Scientific

**Contact name**

Dr Eleanor Barton

**ORCID ID**

<https://orcid.org/0000-0003-0381-810X>

**Contact details**

Learning and Research Building  
Southmead Hospital  
White British  
United Kingdom  
BS10 5NB  
+44 (0)1174148033  
eleanor.barton@nbt.nhs.uk

**Additional identifiers**

**Integrated Research Application System (IRAS)**

322486

**Protocol serial number**

5343

## Study information

**Scientific Title**

Assessing experience, safety, and outcomes of the Passio Pump Drainage System – a randomised, controlled crossover, exploratory study

**Acronym**

AESOP

**Study objectives**

To gather preliminary data regarding the safety, efficacy and tolerability of the Passio Pump Drainage System in comparison to the BD PleurX Pleural Catheter System.

**Ethics approval required**

Ethics approval required

**Ethics approval(s)**

approved 14/02/2024, Liverpool Central (2 Redman Place, London, E20 1JQ, United Kingdom; +44 (0)207 104 8118; liverpoolcentral.rec@hra.nhs.uk), ref: 24/NW/0020

**Study design**

Single-centre crossover 1:1 randomized controlled trial

**Primary study design**

Interventional

**Study type(s)**

Quality of life, Safety, Efficacy

**Health condition(s) or problem(s) studied**

Malignant pleural effusion

**Interventions**

Participants will be randomised to IPC insertion with either a Bearpac Passio catheter or a standard catheter (BD PleurX). After 2 weeks, they will cross over to the alternative drainage system for a further 2 weeks so that all patients experience both drainage systems.

Follow-up will occur 2 and 4 weeks post IPC insertion, with data collected on patient-reported outcome measures, analgesia use, drainage volumes, the person performing each drainage, adverse events and additional comments the participants may have about their experience.

Randomisation will be by a randomisation module within the bespoke REDCap database for the project.

**Intervention Type**

Device

**Phase**

Not Applicable

**Drug/device/biological/vaccine name(s)**

Bearpac Passio catheter, standard catheter (BD PleurX)

**Primary outcome(s)**

1. Safety will be evaluated using the number and type of device related adverse events at 28 days post IPC insertion
2. Patient reported outcomes in terms of chest pain and breathlessness will be measured using the mean change in self-reported pain and breathlessness scores, measured pre- and post- each IPC drainage (3-5 x weekly)

**Key secondary outcome(s)**

The overall patient experience of study involvement and use of both devices will be evaluated in semi-structured interviews arranged at the participants' convenience following their 28 day follow up.

**Completion date**

17/07/2025

**Eligibility****Key inclusion criteria**

1. Confirmed presence of recurrent, symptomatic malignant effusion requiring long-term, intermittent drainage with an indwelling pleural catheter
2. Participant normally lives within the catchment area of North Bristol NHS Trust and is unlikely to relocate within 1 month
3. Aged 18 years or over
4. Able to provide informed consent

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Lower age limit**

18 years

**Upper age limit**

110 years

**Sex**

All

**Total final enrolment**

### **Key exclusion criteria**

1. Known or suspected pleural cavity infection or sepsis
2. Known or suspected uncorrected coagulopathy
3. Contraindication to indwelling pleural catheter insertion
4. Anticipated survival of less than 1 month
5. Patient is a prisoner or young offender in the custody of HM Prison Service or an offender supervised by the probation service in England or Wales

### **Date of first enrolment**

01/06/2024

### **Date of final enrolment**

17/06/2025

## **Locations**

### **Countries of recruitment**

United Kingdom

England

### **Study participating centre**

**North Bristol NHS Trust**

Southmead Hospital

Southmead Road

Westbury-on-trym

Bristol

United Kingdom

BS10 5NB

## **Sponsor information**

### **Organisation**

North Bristol NHS Trust

### **ROR**

<https://ror.org/036x6gt55>

## **Funder(s)**

**Funder type**

Industry

**Funder Name**

Bearpac Plc

## **Results and Publications**

**Individual participant data (IPD) sharing plan**

The data-sharing plans for the current study are unknown and will be made available at a later date

**IPD sharing plan summary**

Data sharing statement to be made available at a later date